Overview of Adverse Events Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

References (66)

1. 1 Correspondence - Tranexamic acid for traumatic brain injury [DOI]
2. 2 Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma [DOI]
3. 3 Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia [DOI]
4. 4 Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia [DOI]
5. 5 Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma [DOI]
6. 6 Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia [DOI]
7. 7 The pro- and anti-inflammatory properties of the cytokine interleukin-6 [DOI]
8. 8 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial [DOI]
9. 9 Current concepts in the diagnosis and management of cytokine release syndrome [DOI]
10. 10 Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia [DOI]
11. 11 IL-6 as a keystone cytokine in health and disease [DOI]
12. 12 Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia [DOI]
13. 13 Chimeric antigen receptor T-cell therapy — assessment and management of toxicities [DOI]
14. 14 Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial [DOI]
15. 15 CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients [DOI]
16. 16 CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia [DOI]
17. 17 Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. [DOI]
18. 18 Cytokine release syndrome [DOI]
19. 19 The Basic Principles of Chimeric Antigen Receptor Design [DOI]
20. 20 Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells [DOI]
21. 21 Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells [DOI]
22. 22 CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy [DOI]
23. 23 Isolation of cDNA clones encoding T cell-specific membrane-associated proteins [DOI]
24. 24 Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy [DOI]
25. 25 Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults [DOI]
26. 26 Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia [DOI]
27. 27 Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells [DOI]
28. 28 Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia [DOI]
29. 29 Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management [DOI]
30. 30 Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm [DOI]
31. 31 Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib [DOI]
32. 32 Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma [DOI]
33. 33 Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma [DOI]
34. 34 Targeting tumours with genetically enhanced T lymphocytes [DOI]
35. 35 Swelling of the optic nerve head: a staging scheme [DOI]
36. 36 Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy [DOI]
37. 37 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors [DOI]
38. 38 Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [DOI]
39. 39 Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells [DOI]
40. 40 Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates [DOI]
41. 41 Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells [DOI]
42. 42 Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy [DOI]
43. 43 Cytokine release syndrome and neurotoxicity after CD 19 chimeric antigen receptor‐modified ( CAR ‐) T cell therapy [DOI]
44. 44 Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function [DOI]
45. 45 Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels [DOI]
46. 46 The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review [DOI]
47. 47 Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. [DOI]
48. 48 Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience [DOI]
49. 49 Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. [DOI]
50. 50 Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. [DOI]
51. 51 ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells [DOI]
52. 52 KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma [DOI]
53. 53 Recommendations for the management of hemophagocytic lymphohistiocytosis in adults [DOI]
54. 54 The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells [DOI]
55. 55 IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome [DOI]
56. 56 Managing the toxicities of CAR T‐cell therapy [DOI]
57. 57 Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma [DOI]
58. 58 CAR T‐cell therapy: Full speed ahead [DOI]
59. 59 DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality [DOI]
60. 60 In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy [DOI]
61. 61 Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. [DOI]
62. 62 Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies [DOI]
63. 63 Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma [DOI]
64. 64 IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell [DOI]
65. 65 Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias [DOI]
66. 66 Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Ameliorative Histological Effects of Aqueous Neem Leaf Extract (Azadirachta indica) on Lead Induced Neurotoxicity of Lateral Geniculate Body of Adult Wistar Rats — shares topic coverage
• Mechanisms of Prooxidants in NeuroInflammatory Processes and Clinical Manifestations — shares topic coverage
• Iatrogenic Baclofen Neurotoxicity in End Stage Renal Disease: A Case Report and Review of Literature — shares topic coverage
• The Roles of Hydrogen Peroxide Exposure in the Toxic Aggregation of Alpha-synuclein and Translocation of DNA Methyltransferase-1 in Human Neuroblastoma Cell Model of Parkinson's Disease — shares topic coverage
• Impact of Inhaled Carbon Soot Particulate Matter (PM10) on Brain Histology Using Wistar Rats — shares topic coverage